# Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

> **NCT02320721** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1014 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Glargine (HOE901 - U300)
- **DRUG:** Insulin Glargine (HOE901 - U100)
- **DRUG:** Background therapy

## Key facts

- **NCT ID:** NCT02320721
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 1014 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320721, "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02320721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*